Palbociclib

Palbociclib · CDK4/6 inhibitor

For HR-positive, HER2-negative advanced or metastatic breast cancer

75/100/125mg capsules Once daily oral 21-day cycle

Therapeutic Areas

Oncology

Marketed Products

Palbociclib

Modality

Palbociclib

Core Products

Osimertinib · 3rd-generation EGFR TKI

Bevacizumab · Anti-VEGF monoclonal antibody

Rituximab · Anti-CD20 monoclonal antibody

Creating a Healthier Future Together

Explore our innovative products and pipeline, and see how Poseidon brings hope to patients worldwide